FindTrial
Sign In

To determine whether 3 doses of vaccines for rabies post exposure prophylaxis are enough to protect against the development of the disease

Anti Rabies Virus Glycoprotein Antibody titres after three doses of intradermal Post Exposure Prophylaxis in children and adolescents under 18 years of age - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/08/056607
Enrollment
75
Registered
2023-08-17
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: W540- Bitten by dog

Interventions

Control Intervention1: nil: nil

Sponsors

Department of Pediatrics
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children and adolescents under 18 years of age presenting for the fourth dose of rabies post exposure prophylaxis

Exclusion criteria

Exclusion criteria: 1.known case of immunodeficiency states. 2.history of receiving any dose of anti rabies vaccine prior to current animal exposure.

Design outcomes

Primary

MeasureTime frame
Proportion of children with IgG anti rabies virus glycoprotein titres equal to or more than 0.5 EU/ml after 3 doses of Intradermal post exposure rabies prophylaxis in children & adolescents under 18 years of ageTimepoint: day 28 of rabies post exposure prophylaxis—

Secondary

MeasureTime frame
adverse events following 3 doses of intradermal post exposure rabies prophylaxisTimepoint: on day 28 of rabies post exposure prophylaxis—

Countries

India

Contacts

Public ContactDr Shirin Rana

Maulana Azad Medical College and Associated Lok Nayak Hospital

doctoranuragagarwal@gmail.com9810409625

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026